A team driven by a singular mission

Founder of Avipero Ltd and Avipero Bio, and previously a principal investigator at Edinburgh University with a long-standing interest in tissue repair. She is the principal inventor of the concept of beta1 integrin's role in tissue repair and senescence.

Over 30 years of international leadership experience across biotechnology, global health and medical research. Experienced in building start-ups (2 in biotech). He also sits on the Audit Committee of the EDCTP, a €2 Billion public-public partnership for Global Health research between Europe and Africa.

President of Proventus Consulting. Experienced oncology product development, brand positioning and differentiation and marketing pharmaceutical executive at Eli-Lilly such as ALIMTA® (pemetrexed), GEMZAR® (gemcitabine) and VERZENIO® (abemaciclib).

Global Head of Business Development & Licensing and Mergers & Acquisitions at Sandoz AG. Previously Vice President of Business Development and Alliance Management at HIKMA Pharmaceuticals and Senior Director of Marketing Analytics and Business Insight at Abbott Laboratories.

A seasoned biopharmaceutical executive and clinical development leader with over 25 years of experience advancing innovative therapies from discovery through global regulatory approval. Currently serves as CEO & President of Vaderis Therapeutics. Past roles include co-founder and former COO of Phathom Pharmaceuticals, Entrepreneur-in-Residence at Frazier Life Sciences, and senior positions at Takeda Pharmaceuticals and Abbott Laboratories.

A partner at WG Partners with over 25 years experience of leading corporate transactions. Held senior positions at ABN AMRO, Merrill Lynch European Healthcare Equity Research, and Sudbrook Associates.